Abstract: Aircraft, auto speed brake control systems, and methods for controlling drag of an aircraft are provided. In one example, an aircraft includes an aircraft structure. A drag device is operatively coupled to the aircraft structure between a stowed and a deployed position and/or an intermediate deployed position. A speed brake controller is in communication with the drag device to control movement. An autothrottle-autospeedbrake controller is in communication with the speed brake controller and is configured to receive data signals. The autothrottle-autospeedbrake controller is operative to direct the speed brake controller to control movement of the drag device between the stowed position and the deployed position and/or the intermediate deployed position in response to at least one of the data signals.

Abstract: The processor supplies flight commands to the flight control system by selectively blending pilot input with control signals from the autopilot. The processor generates a projected recovery trajectory through successive iterations, each beginning at the current aircraft location and using a recovery constraint selectable by the processor to influences a degree of flight aggressiveness. A detection system that identifies and invokes a state of threat existence if a threat exists along the projected recovery trajectory. The processor during threat existence in a first iteration commands an initial soft recovery, with permitted blended pilot input. If the threat exists on subsequent iteration, the processor commands a more aggressive recovery while attenuating blended pilot input.

Abstract: Avionics systems, aircraft, and methods are provided. An avionics system for a subject aircraft includes an intruder aircraft detection device and a processor. The processor is programmed to: identify an intruder aircraft using the intruder aircraft detection device; predict a future path of the intruder aircraft; estimate strength, size, and location characteristics of a wake vortex created by the intruder aircraft at future points in time along the future path; calculate a potential trajectory with potential positions of the subject aircraft at each of the future points in time; compare the potential positions with the strength, size, and location characteristics of the wake vortex at each of the future points in time to identify a wake conflict; and maneuver the subject aircraft based on the wake conflict.

Abstract: A projected recovery trajectory for an aircraft autopilot system is precomputed by providing a stored set of predefined recovery mode segments, including: a mode 1 segment that models the aircraft coasting; a mode 2 segment that models the aircraft executing a nose high recovery; a mode 3 segment that models the aircraft executing a nose low recovery; a mode 4 segment that models the aircraft executing a throttle only recovery; and a mode 5 segment that models the aircraft executing a terrain avoidance recovery. A processor generates at least one projected recovery trajectory based on a current state of the aircraft, where the processor selectively concatenates selected ones of the predefined recovery mode segments into a sequence and uses that sequence to generate the projected trajectory.

Abstract: The aircraft threat envelope protection system employs a threat envelope data structure in a computer-readable medium that stores at least one trigger condition for each of a plurality of different types of threats associated with the aircraft, and modeled using a common schema. A processor computes plural different projected trajectories representing different possible aircraft paths through spacetime. The processor associates at least some of the plurality of the threats to specific trigger points in spacetime along each of the projected trajectories. The processor will deprecate ones of the projected trajectories when they are deemed not viable to recover from a threat. The processor initiates an aircraft protective response when all projected trajectories but one have been deprecated and the aircraft is within a predetermined proximity to the closest trigger point in spacetime along the non-deprecated trajectory.

Abstract: The present invention relates to an active (immunostimulatory) composition comprising at least one RNA, preferably an mRNA, encoding at least two (preferably different) antigens capable of eliciting an (adaptive) immune response in a mammal wherein the antigens are selected from the group consisting of PSA (Prostate-Specific Antigen), PSMA (Prostate-Specific Membrane Antigen), PSCA (Prostate Stem Cell Antigen), and STEAP (Six Transmembrane Epithelial Antigen of the Prostate), The invention furthermore relates to a vaccine comprising an active (immunostimulatory) composition, and to the use of the active (immunostimulatory) composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of prostate cancer (PCa), preferably of neoadjuvant and/or hormone-refractory prostate cancers, and diseases or disorders related thereto.

Abstract: The present invention relates to an active (immunostimulatory) composition comprising at least one RNA, preferably an mRNA, encoding at least two (preferably different) antigens capable of eliciting an (adaptive) immune response in a mammal wherein the antigens are selected from the group consisting of PSA (Prostate-Specific Antigen), PSMA (Prostate-Specific Membrane Antigen), PSCA (Prostate Stem Cell Antigen), and STEAP (Six Transmembrane Epithelial Antigen of the Prostate). The invention furthermore relates to a vaccine comprising an active (immunostimulatory) composition, and to the use of the active (immunostimulatory) composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of prostate cancer (PCa), preferably of neoadjuvant and/or hormone-refractory prostate cancers, and diseases or disorders related thereto.

Abstract: The present invention relates to an active (immunostimulatory) composition comprising at least one RNA, preferably a mRNA, encoding at least two (preferably different) antigens capable of eliciting an (adaptive) immune response in a mammal. The invention furthermore relates to a vaccine comprising said active (immunostimulatory) composition, and to the use of said active (immunostimulatory) composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of lung cancer, particularly of non-small cell lung cancers (NSCLC), preferably selected from the three main sub-types squamous cell lung carcinoma, adenocarcinoma and large cell lung carcinoma, or of disorders related thereto. Finally, the invention relates to kits, particularly to kits of parts, containing the active (immunostimulatory) composition and/or the vaccine.

Abstract: Collision warning systems, collision warning devices, and methods of operating collision warning systems are disclosed herein. A collision warning system includes, but is not limited to, a plurality of proximity sensors and a computer device. The plurality of proximity sensors are configured to mount on an aircraft and to generate a proximity signal. The computer device is communicatively coupled with the plurality of proximity sensors and is configured to determine a location in which the collision warning system is located, where the location includes at least one of a country and a region. The computer device is further configured to select an active linguistic profile based on the location, where the active linguistic profile includes at least one of a language and a dialect. The computer device is yet further configured to alert ground crew of potential collisions using the active linguistic profile and based on the proximity signal.

Abstract: A durable pet having a flat polyurethane foam core, a first polyurethane layer bonded to the top surface of the core, and a second polyurethane layer bonded to the sides of the core, and a method for making such a bed. The first polyurethane layer has a thickness of about 0.05 to 0.25 inches and a hardness of about 20 to 70 durometers. The second polyurethane layer has a thickness of about 0.05 to 0.3 inches and a hardness of about 50 to 100 durometers. The pet bed may have a third polyurethane layer bonded to the bottom of the core, the third layer having a thickness of about 0.05 to 0.25 inches and a hardness of about 20 to 100 durometers. The first, second and third layers typically completely encase the core.

Abstract: The present invention relates to an active (immunostimulatory) composition comprising at least one RNA preferably an mRNA, encoding at least two (preferably different) antigens capable of eliciting an (adaptive) immune response in a mammal wherein the antigens are selected from the group consisting of PSA (Prostate-Specific Antigen), PSMA (Prostate-Specific Membrane Antigen), PSCA (Prostate Stem Cell Antigen), and STEAP (Six Transmembrane Epithelial Antigen of the Prostate). The invention furthermore relates to a vaccine comprising an active (immunostimulatory) composition, and to the use of the active (immunostimulatory) composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of prostate cancer (PCa), preferably of neoadjuvant and/or hormone-refractory prostate cancers, and diseases or disorders related thereto.

Abstract: The present invention relates to an active (immunostimulatory) composition comprising at least one RNA, preferably a mRNA, encoding at least two (preferably different) antigens capable of eliciting an (adaptive) immune response in a mammal. The invention furthermore relates to a vaccine comprising said active (immunostimulatory) composition, and to the use of said active (immunostimulatory) composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of lung cancer, particularly of non-small cell lung cancers (NSCLC), preferably selected from the three main sub-types squamous cell lung carcinoma, adenocarcinoma and large cell lung carcinoma, or of disorders related thereto. Finally, the invention relates to kits, particularly to kits of parts, containing the active (immunostimulatory) composition and/or the vaccine.

Abstract: The present invention relates to an active (immunostimulatory) composition comprising at least one RNA, preferably a mRNA, encoding at least two (preferably different) antigens capable of eliciting an (adaptive) immune response in a mammal. The invention furthermore relates to a vaccine comprising said active (immunostimulatory) composition, and to the use of said active (immunostimulatory) composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of lung cancer, particularly of non-small cell lung cancers (NSCLC), preferably selected from the three main sub-types squamous cell lung carcinoma, adenocarcinoma and large cell lung carcinoma, or of disorders related thereto. Finally, the invention relates to kits, particularly to kits of parts, containing the active (immunostimulatory) composition and/or the vaccine.

Abstract: The present invention relates to an active (immunostimulatory) composition comprising at least one RNA, preferably an mRNA, encoding at least two (preferably different) antigens capable of eliciting an (adaptive) immune response in a mammal wherein the antigens are selected from the group consisting of PSA (Prostate-Specific Antigen), PSMA (Prostate-Specific Membrane Antigen), PSCA (Prostate Stem Cell Antigen), and STEAP (Six Transmembrane Epithelial Antigen of the Prostate). The invention furthermore relates to a vaccine comprising an active (immunostimulatory) composition, and to the use of the active (immunostimulatory) composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of prostate cancer (PCa), preferably of neoadjuvant and/or hormone-refractory prostate cancers, and diseases or disorders related thereto.

Abstract: Aircraft, control-by-wire systems, and controllers are provided. The aircraft includes a flight control surface and a control-by-wire system. The control-by-wire system includes an input device and a controller. The input device is configured to control the flight control surface. The controller is communicatively coupled with the input device and configured to automatically offset a neutral force position of the input device based on a deviation of the aircraft from a reference condition while the aircraft is operated in a manual flight mode.

Abstract: The disclosed embodiments relate to a flight control computer for an aircraft. The flight control computer includes an inertial sensor integrated or incorporated within the flight control computer.

Abstract: The present invention relates to an active (immunostimulatory) composition comprising at least one RNA, preferably an mRNA, encoding at least two (preferably different) antigens capable of eliciting an (adaptive) immune response in a mammal wherein the antigens are selected from the group consisting of PSA (Prostate-Specific Antigen), PSMA (Prostate-Specific Membrane Antigen), PSCA (Prostate Stem Cell Antigen), and STEAP (Six Transmembrane Epithelial Antigen of the Prostate). The invention furthermore relates to a vaccine comprising an active (immunostimulatory) composition, and to the use of the active (immunostimulatory) composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of prostate cancer (PCa), preferably of neoadjuvant and/or hormone-refractory prostate cancers, and diseases or disorders related thereto.

Abstract: The present invention relates to a composition comprising at least one mRNA encoding a combination of antigens capable of eliciting an (adaptive) immune response in a mammal, wherein the antigens are selected from the group consisting of PSA (Prostate-Specific Antigen), PSMA (Prostate-Specific Membrane Antigen), PSCA (Prostate Stem Cell Antigen), STEAP (Six Transmembrane Epithelial Antigen of the Prostate), MUC1 (Mucin 1) and PAP (Prostatic acid phosphatase). The invention furthermore relates to a vaccine comprising at least one mRNA encoding such a combination of antigens and to the use of said composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of prostate cancer (PCa), preferably of prostate adenocarcinoma, locally limited, locally advanced, metastatic, castration-resistant (hormone-refractory), metastatic castration-resistant and non-metastatic castration-resistant prostate cancers, and diseases or disorders related thereto.

Abstract: The present invention relates to an active (immunostimulatory) composition comprising at least one RNA, preferably a mRNA, encoding at least two (preferably different) antigens capable of eliciting an (adaptive) immune response in a mammal. The invention furthermore relates to a vaccine comprising the active (immunostimulatory) composition, and to the use of the active (immunostimulatory) composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of lung cancer, particularly of non-small cell lung cancers (NSCLC), preferably selected from the three main sub-types squamous cell lung carcinoma, adenocarcinoma and large cell lung carcinoma, or of disorders related thereto. Finally, the invention relates to kits, particularly to kits of parts, containing the active (immunostimulatory) composition and/or the vaccine.

Abstract: Aircraft, control-by-wire systems, and controllers are provided. The aircraft includes a flight control surface and a control-by-wire system. The control-by-wire system includes an input device and a controller. The input device is configured to control the flight control surface. The controller is communicatively coupled with the input device and configured to automatically offset a neutral force position of the input device based on a deviation of the aircraft from a reference condition while the aircraft is operated in a manual flight mode.